Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ENTA Relative to the S&P 500

ENTA Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Enanta Pharmaceuticals, Inc. (NASD:ENTA) seasonal charts above shows that a Buy Date of October 24 and a Sell Date of March 13 has resulted in a geometric average return of 14.96% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 38.64% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company’s inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

To download ENTA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ENTA